Every fifth second someone in the world develops Alzheimer’s disease. There is a huge need for more research and effective treatments. September 2018 marks the seventh World Alzheimer’s Month, an international campaign to raise awareness and challenge the stigma that surrounds the disease.
Professor Lars Lannfelt and his co-workers at Uppsala University, in Sweden, made a clinical observation in the late 1990’s of elevated protofibrils in patients with the Arctic mutation. This led to the hypothesis that soluble protofibrils of amyloid-beta was a good target for treatment. This discovery led to the founding of BioArctic in 2003.
At BioArctic, we are convinced that we can contribute to treatment of devastating diseases like Alzheimer’s disease by science. One of BioArctic’s most important objectives is to develop innovative and effective disease-modifying treatment against Alzheimer’s disease. We are currently working with five Alzheimer projects.
Our most advanced project, BAN2401, is a unique antibody developed to selectively target soluble, toxic aggregated amyloid-beta, i. e. protofibrils, in the brain of Alzheimer patients. At the world largest Alzheimer conference (AAIC 2018) in July, the 18-month results from the study with BAN2401 were presented and demonstrated that the Phase 2b study in 856 early Alzheimer patients is the first large clinical study to show a consistent effect on several clinical scales and several biomarkers in pre-specified analyses. BAN2401 shows also a good tolerability profile.
” We are proud of what we have accomplished so far. These results are important for BioArctic, the Alzheimer field of research and give new hope for patients and their families,” said Gunilla Osswald, Ph.D., CEO.